Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase II trial of revolutionary migraine treatment completed ahead of schedule

Sep. 14, 1998

Roche to withdraw support for development of Kyowa Hakko's antiparkinsonian

Sep. 14, 1998

Neuroprotective effects of S-12024-2 demonstrated in rat model of neurodegeneration

Sep. 14, 1998

Synthelabo compounds act as 5-HT receptor ligands

Sep. 14, 1998

New anticonvulsant option now available in U.K.

Sep. 14, 1998

Genzyme General to commercialize and distribute Biogen's Avonex in Japan

Sep. 11, 1998

New anxiolytic PBI derivative discovered at R.W. Johnson

Sep. 11, 1998

Novel binary compounds with agonist-antagonist effects in vivo

Sep. 11, 1998

SB reports on potent analgesics with fewer side effects

Sep. 11, 1998

DuPont identifies SP-904 as potent and selective CRF1 receptor antagonist

Sep. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...